









Markets
/
Stocks
/
nasdaq-zvra
/

Zevra Therapeutics Inc

ZVRA

7.940USD

+0.610+8.32%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

434.15MMarket Cap

LossP/E TTM



Zevra Therapeutics Inc

7.940

+0.610+8.32%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

70 / 175

Overall Ranking

197 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

23.714

Target Price

+223.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 132.38% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 23.61M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 294.11.

Undervalued

The company’s latest PE is -85.93, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 33.85M shares, decreasing 11.22% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.95M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 8.22, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 25.88M, representing a year-over-year increase of 481.73%, while its net profit experienced a year-over-year increase of 474.94%.

Score

Industry at a Glance

Previous score

8.22

Change



Financials

6.48

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -79.33, which is -94.90% below the recent high of -4.05 and 91.26% above the recent low of -6.93.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 70/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Zevra Therapeutics Inc is 25.00, with a high of 29.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

23.714

Target Price

+223.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Zevra Therapeutics Inc

ZVRA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.62, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 9.27 and the support level at 6.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

0.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.103

Sell

RSI(14)

36.652

Neutral

STOCH(KDJ)(9,3,3)

25.138

Buy

ATR(14)

0.422

High Vlolatility

CCI(14)

-54.759

Neutral

Williams %R

65.022

Sell

TRIX(12,20)

-1.205

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

7.502

Buy

MA10

7.893

Buy

MA20

8.566

Sell

MA50

10.167

Sell

MA100

9.465

Sell

MA200

8.715

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 61.90%, representing a quarter-over-quarter decrease of 14.53%. The largest institutional shareholder is The Vanguard, holding a total of 2.95M shares, representing 5.26% of shares outstanding, with 0.04% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Woodline Partners LP

4.62M

+11.50%

Adage Capital Management, L.P.

3.62M

-0.88%

BlackRock Institutional Trust Company, N.A.

3.78M

+0.48%

The Vanguard Group, Inc.

Star Investors

2.83M

+0.06%

Fidelity Management & Research Company LLC

2.19M

-0.71%

Rubric Capital Management LP

1.22M

+97.64%

Nantahala Capital Management, LLC

1.47M

-37.11%

Geode Capital Management, L.L.C.

1.23M

+3.79%

State Street Global Advisors (US)

1.18M

+0.34%

683 Capital Management LLC

1.23M

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.94, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 2.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.